نظرة عامة

البيانات الصحفية والأخبار

ابق على اطلاع بأحدث الإنجازات والشراكات والمعالم في PGxAI. تعكس بياناتنا الصحفية وتحديثات الأخبار التزامنا المستمر بتحويل الرعاية الصحية من خلال الطب الدقيق القائم على الذكاء الاصطناعي.

البحث حسب العنوان

Upload Your Own Genetic Data: Instant Drug-Sensitivity Insights Now in All Base Models

PGxAI now offers free direct upload of custom genomic files in every base model, delivering instant, compound-specific drug-sensitivity readouts. Paid API endpoints remain available for high-volume, workflow integration.

أبرز النقاط

Supports VCF data from all major platforms

<10 s per-compound sensitivity scoring, expandable to full panels

Scalable, paid REST API and automated reporting for enterprise deployments

Bruce Broussard, Former Humana CEO, Joins PGxAI as Advisor for Reimbursement Strategy

PGxAI appoints Bruce Broussard, former Humana CEO, to shape reimbursement strategy and align precision-medicine innovations with value-based payment models.

أبرز النقاط

Spearheaded Humana’s shift to value-based care, cutting avoidable hospitalizations and total cost of care

Deep expertise in payer-provider alignment, Medicare Advantage, home-health integration, and predictive analytics

Advises PGxAI on reimbursement pilots and market-access strategy for pharmacogenomic decision support

Drug-Drug Interaction Module—FDA-Label Powered, Terminal-Ready—Now Live in All Open Models

PGxAI introduces an FDA-label-derived DDI module, offering real-time interaction checks in both open CLI models and enterprise API workflows.

أبرز النقاط

Extracted interaction data from 40,000+ FDA labels, covering 1,300+ unique drugs

<10s risk assessment per query with severity grading and label citations

Free terminal testing for all open models; scalable API available for production deployments

PGxAI Unveils AI-Driven Genetic Tool to Personalize GLP-1 Drugs Including Ozempic®

PGxAI has released an AI-driven genetic report that tailors GLP-1 therapies—including semaglutide brands Ozempic® and Wegovy®—to each patient’s genome, flagging high-risk variants and delivering actionable dosing or alternative-drug guidance within minutes via EHR integration.

أبرز النقاط

Identifies risk variants in up to ⅓ of semaglutide patients

Covers 10+ GLP-1, dual-incretin, and CNS-based weight-loss drugs

Real-time decision support through InterSystems HealthShare

PGxAI Debuts Deneb, an AI Model Revolutionizing Drug Development for Biopharma

PGxAI has launched Deneb, an AI pharmacogenetics model for biopharma and CROs that fuses molecular, physicochemical, and genomic data to deliver real-time PGx guidance, cutting trial costs and speeding drugs to market.

أبرز النقاط

Real-time PGx insights for cohort, dose, safety

Automates multi-omics + structure data; shortens trials

Powered by NVIDIA, Microsoft, InterSystems stack

Automated Phenoconversion Arrives: Real-Time, Context-Aware Drug-Response Scoring in Every Base Model

PGxAI has embedded automated phenoconversion in all base models, instantly recalibrating genotype-based predictions to reflect co-medications and clinical modifiers; the feature is live in the web portal and available via enterprise REST API.

أبرز النقاط

Context-aware phenotype adjustment for CYP450 and 20+ additional enzymes

<10 s recalculation per drug, supporting batch analysis through paid API

Seamless upgrade—no extra configuration for existing base-model users

PGxAI Debuts Vega, an AI Model Set to Disrupt Precision Medicine

PGxAI has unveiled Vega, an AI-powered pharmacogenetics model that instantly converts a patient’s genomic data into drug-specific treatment recommendations, covering 1,200 drugs and 350 genes—vastly surpassing traditional panels.

أبرز النقاط

1,200 drugs / 350 genes analyzed in minutes

Cuts adverse-reaction risk via automated guideline interpretation

Built with GenAI; integrates into EHRs through InterSystems HealthShare

Revolutionizing Precision Medicine: PGxAI Raises $1.5 Million in Funding for AI-Powered Pharmacogenetics Platform

PGxAI has raised $1.5 million to scale its AI-powered pharmacogenetics platform, funding upgrades to its VectorSearch and GenAI tools and deepening its partnership with InterSystems to deliver ultra-precise, genome-guided prescribing.

أبرز النقاط

$1.5M round accelerates tech development

Boosts VectorSearch & GenAI for dose, drug-selection, DDI insights

Leverages InterSystems’ vast patient data to sharpen precision medicine

The Ventures Award: The World's Premier Stage for Startup Excellence

PGxAI captured the top prize at The Ventures Award—Silicon Valley’s roaming startup showcase—outshining hundreds of global contenders with its AI-powered pharmacogenomics platform. The tour now heads to Chicago on 7 Feb 2025 before expanding to other tech hubs worldwide.

أبرز النقاط

PGxAI wins flagship Ventures Award

30-city, 19-country pitch circuit

Next event: Chicago, 7 Feb 2025

PGxAI Launches Sirius, an AI‑Powered Pharmacogenetics Model

PGxAI has launched Sirius, an AI-driven pharmacogenetics model that tailors drug choice, dosage, and interaction management to each patient’s genome, enabling ultra-precision prescribing for hospitals, labs, and CROs.

أبرز النقاط

Covers 730 drugs and 40 key pharmacogenes—more than twice the scope of typical solutions—aiming to avert up to 30% of adverse drug reactions.

Leverages partnerships with Nvidia, Microsoft, Google, Meta, AWS, and InterSystems, integrating seamlessly into EHR workflows via HealthShare.

Ambitious roadmap: expand to 1 700 drugs in 2025, add GenAI and federated-learning upgrades by 2026, and harness >1 billion real-world outcomes by 2030.

IPA’s Subsidiary BioStrand and PGxAI Announce Strategic Collaboration

BioStrand (ImmunoPrecise) and PGxAI are partnering to build an AI-driven pharmacogenomics model on BioStrand’s LENSai platform to deliver personalized drug-response predictions and speed up LENSai API adoption.

أبرز النقاط

Integrates LENSai’s multi-omics AI with PGxAI’s real-world genomic data to forecast efficacy, dose, and safety.

Aims to cut the >30% rate of drug-related adverse events and improve precision prescribing.

Targets the $400B prescription market, unlocking new revenue as the LENSai API scales.

ابق على اتصال

نتطلع إلى المستقبل، مهمتنا لا تزال ثابتة

ابق على اطلاع بأحدث الإنجازات والشراكات والمعالم في PGxAI. تعكس بياناتنا الصحفية وتحديثات الأخبار التزامنا المستمر بتحويل الرعاية الصحية من خلال الطب الدقيق القائم على الذكاء الاصطناعي.

تحديثات البريد الإلكتروني

اشترك في نشرتنا الإخبارية للحصول على رؤى شهرية وإطلاق المنتجات والأحداث القادمة.

لينكد إن

تابع PGxAI للحصول على تحديثات في الوقت الفعلي حول اتجاهات الصناعة وإعلانات الشركة.

استفسارات وسائل الإعلام

للعلاقات الصحفية والإعلامية، أرسل بريدًا إلكترونيًا إلى admin@pgx.ai أو اتصل بالرقم +1 (415) 246-5322.

تواصل معنا

هل أنت مستعد لتشكيل مستقبل الطب الدقيق؟

تستمر PGxAI في التطور مع كل تطوير، مما يعزز مهمتنا لتقديم رعاية شخصية تفيد المرضى ومقدمي الخدمات وجميع أصحاب المصلحة في النظام البيئي للرعاية الصحية.

راسلنا عبر البريد الإلكتروني: admin@pgxai.com

اتصل بنا: +1 (415) 246-5322

جدولة عرض توضيحي